Headlines about Novogen Limited (NASDAQ:NVGN) have trended positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novogen Limited earned a media sentiment score of 0.36 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.5392130292341 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Novogen Limited (NASDAQ:NVGN) traded up 7.19% on Tuesday, reaching $3.43. 12,626 shares of the company traded hands. Novogen Limited has a 52-week low of $0.70 and a 52-week high of $3.82. The firm’s market cap is $16.57 million. The stock has a 50-day moving average price of $1.90 and a 200-day moving average price of $1.43.
Several research firms recently weighed in on NVGN. ValuEngine cut shares of Novogen Limited from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research cut shares of Novogen Limited from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd.
TRADEMARK VIOLATION NOTICE: This news story was reported by BBNS and is the property of of BBNS. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/novogen-limited-nasdaqnvgn-receiving-favorable-news-coverage-analysis-shows-updated/1305409.html.
Novogen Limited Company Profile
Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.
Receive News & Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related companies with our FREE daily email newsletter.